Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group

Ruxolitinib improves splenomegaly and other disease-related symptoms in patients with myelofibrosis, but over time, many patients lose this benefit. It is difficult to determine whether this is due to resistance or intolerance to the drug; thus, we have used the more inclusive term of ruxolitinib fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Vikas, Cerquozzi, Sonia, Foltz, Lynda, Hillis, Christopher, Devlin, Rebecca, Elsawy, Mahmoud, Grewal, Kuljit, Hamm, Caroline, McNamara, Caroline, Sirhan, Shireen, Leber, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Clinical Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359776/
https://www.ncbi.nlm.nih.gov/pubmed/32134707
http://dx.doi.org/10.1200/JOP.19.00506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359776/
https://www.ncbi.nlm.nih.gov/pubmed/32134707
http://dx.doi.org/10.1200/JOP.19.00506

Ejemplares similares